{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T11:39:31Z","timestamp":1784547571526,"version":"3.55.0"},"reference-count":75,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,12,8]],"date-time":"2018-12-08T00:00:00Z","timestamp":1544227200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.biopha.2018.12.034","type":"journal-article","created":{"date-parts":[[2018,12,13]],"date-time":"2018-12-13T13:45:22Z","timestamp":1544708722000},"page":"796-802","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Duchenne muscular dystrophy: Focus on arachidonic acid metabolites"],"prefix":"10.1016","volume":"110","author":[{"given":"Malvina","family":"Hoxha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.biopha.2018.12.034_bib0005","doi-asserted-by":"crossref","first-page":"e49346","DOI":"10.1371\/journal.pone.0049346","article-title":"Exploration of lipid metabolism in relation with plasma membrane properties of Duchenne muscular dystrophy cells: influence of L-carnitine","volume":"7","author":"Le Borgne","year":"2012","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.biopha.2018.12.034_bib0010","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1096\/fj.13-238071","article-title":"The therapeutic potential of skeletal muscle plasticity in Duchenne muscular dystrophy: phenotypic modifiers as pharmacologic targets","volume":"28","author":"Ljubicic","year":"2014","journal-title":"FASEB J."},{"key":"10.1016\/j.biopha.2018.12.034_bib0015","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.2147\/DDDT.S110163","article-title":"Anti-inflammatory drugs for Duchenne muscular dystrophy: focus on skeletal muscle-releasing factors","volume":"10","author":"Miyatake","year":"2016","journal-title":"Drug Des. Devel. Ther."},{"issue":"11","key":"10.1016\/j.biopha.2018.12.034_bib0020","doi-asserted-by":"crossref","first-page":"e49350","DOI":"10.1371\/journal.pone.0049350","article-title":"Treatment with a nitric oxide-donating NSAID alleviates functional muscle ischemia in the mouse model of Duchenne muscular dystrophy","volume":"7","author":"Thomas","year":"2012","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.biopha.2018.12.034_bib0025","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1152\/physrev.00028.2001","article-title":"Function and genetics of dystrophin and dystrophin-related proteins in muscle","volume":"82","author":"Blake","year":"2002","journal-title":"Physiol. Rev."},{"issue":"4","key":"10.1016\/j.biopha.2018.12.034_bib0030","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/ana.24365","article-title":"Clinical phenotypes as predictors of the outcome of skipping around DMD exon 45","volume":"77","author":"Findlay","year":"2015","journal-title":"Ann. Neurol."},{"issue":"6","key":"10.1016\/j.biopha.2018.12.034_bib0035","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1096\/fj.03-1024com","article-title":"Anti-TNF\u03b1 (Remicade\u00ae) therapy protects dystrophic skeletal muscle from necrosis","volume":"18","author":"Grounds","year":"2004","journal-title":"FASEB J."},{"issue":"6","key":"10.1016\/j.biopha.2018.12.034_bib0040","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/S0960-8966(01)00198-5","article-title":"Do immune cells promote the pathology of dystrophin-deficient myopathies?","volume":"11","author":"Spencer","year":"2001","journal-title":"Neuromuscul. Disord."},{"issue":"5","key":"10.1016\/j.biopha.2018.12.034_bib0045","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1002\/mus.20150","article-title":"Localization and early time course of TGF\u2010\u03b21 mRNA expression in dystrophic muscle","volume":"30","author":"Gosselin","year":"2004","journal-title":"Muscle Nerve"},{"issue":"1","key":"10.1016\/j.biopha.2018.12.034_bib0050","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1474-4422(09)70271-6","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management","volume":"9","author":"Bushby","year":"2010","journal-title":"Lancet Neurol."},{"issue":"6","key":"10.1016\/j.biopha.2018.12.034_bib0055","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/0092-8674(87)90579-4","article-title":"Dystrophin: the protein product of the Duchenne muscular dystrophy locus","volume":"51","author":"Hoffman","year":"1987","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.biopha.2018.12.034_bib0060","doi-asserted-by":"crossref","first-page":"796","DOI":"10.3390\/nu10060796","article-title":"Skeletal muscle metabolism in Duchenne and becker muscular dystrophy\u2013implications for therapies","volume":"10","author":"Heydemann","year":"2018","journal-title":"Nutrients"},{"key":"10.1016\/j.biopha.2018.12.034_bib0065","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1007\/s00018-017-2465-5","article-title":"Skeletal muscle secretome in Duchenne muscular dystrophy: a pivotal anti-inflammatory role of adiponectin","volume":"74","author":"Lecompte","year":"2017","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.biopha.2018.12.034_bib0070","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/ana.24214","article-title":"Sildenafil does not improve cardiomyopathy in Duchenne\/Becker muscular dystrophy","volume":"76","author":"Leung","year":"2014","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.biopha.2018.12.034_bib0075","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0152840","article-title":"Safety, tolerability, and pharmacokinetics of SMT C1100, a 2-Arylbenzoxazole utrophin modulator, following single- and multiple-dose administration to pediatric patients with Duchenne muscular dystrophy","volume":"11","author":"Ricotti","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2018.12.034_bib0080","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1056\/NEJM197807132990216","article-title":"Allopurinol in Duchenne\u2019s muscular dystrophy","volume":"299","author":"Thomson","year":"1978","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2018.12.034_bib0085","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/0026-0495(78)90161-0","article-title":"X-linked recessive (Duchenne) muscular dystrophy (DMD) and purine metabolism: effects of oral allopurinol and adenylate","volume":"27","author":"Thomson","year":"1978","journal-title":"Metabolism"},{"key":"10.1016\/j.biopha.2018.12.034_bib0090","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0147634","article-title":"Improved muscle function in Duchenne muscular dystrophy through L-Arginine and metformin: an investigator-initiated, open-label, single-center, proof-of-Concept-Study","volume":"11","author":"Hafner","year":"2016","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.biopha.2018.12.034_bib0095","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/nrrheum.2014.2","article-title":"The skeletal muscle arachidonic acid cascade in health and inflammatory disease","volume":"10","author":"Korotkova","year":"2014","journal-title":"Nat. Rev. Rheumatol."},{"issue":"7","key":"10.1016\/j.biopha.2018.12.034_bib0100","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/j.1440-1681.2006.04394.x","article-title":"Muscle damage in mdx (dystrophic) mice: role of calcium and reactive oxygen species","volume":"33","author":"Whitehead","year":"2006","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"issue":"3","key":"10.1016\/j.biopha.2018.12.034_bib0105","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.plefa.2007.10.002","article-title":"Effects of inhibitors of the arachidonic acid cascade on primary muscle culture from a Duchenne muscular dystrophy patient","volume":"77","author":"Gati","year":"2007","journal-title":"Prostaglandins Leukot. Essent. Fatty Acids"},{"key":"10.1016\/j.biopha.2018.12.034_bib0110","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0960-8966(94)00045-B","article-title":"Phospholipase A2 activity in dystrophinopathies","volume":"5","author":"Lindahl","year":"1995","journal-title":"Neuromuscul. Disord."},{"issue":"18","key":"10.1016\/j.biopha.2018.12.034_bib0115","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1242\/jcs.03184","article-title":"Ca2+-independent phospholipase A2 enhances store-operated Ca2+ entry in dystrophic skeletal muscle fibers","volume":"119","author":"Boittin","year":"2006","journal-title":"J. Cell. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2018.12.034_bib0120","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.bbrc.2009.11.070","article-title":"Phospholipase A 2-derived lysophosphatidylcholine triggers Ca 2+ entry in dystrophic skeletal muscle fibers","volume":"391","author":"Boittin","year":"2010","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"6","key":"10.1016\/j.biopha.2018.12.034_bib0125","first-page":"799","article-title":"Altered long chain fatty acids composition in Duchenne muscular dystrophy erythrocytes","volume":"18","author":"Piperi","year":"2004","journal-title":"In Vivo"},{"key":"10.1016\/j.biopha.2018.12.034_bib0130","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s00401-002-0567-z","article-title":"Induction of hematopoietic prostaglandin D synthase in hyalinated necrotic muscle fibers: its implication in grouped necrosis","volume":"104","author":"Okinaga","year":"2002","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.biopha.2018.12.034_bib0135","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/01.TA.0000057238.75632.7F","article-title":"Low-dose prostacyclin restores an increased protein permeability","volume":"56","author":"Bentzer","year":"2004","journal-title":"J. Trauma"},{"issue":"12","key":"10.1016\/j.biopha.2018.12.034_bib0140","doi-asserted-by":"crossref","first-page":"3338","DOI":"10.1096\/fj.06-7070com","article-title":"Inhibition of myoblast migration by prostacyclin is associated with enhanced cell fusion","volume":"21","author":"Bondesen","year":"2007","journal-title":"FASEB J."},{"key":"10.1016\/j.biopha.2018.12.034_bib0145","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.yexcr.2005.08.009","article-title":"Stretch-induced myoblast proliferation is dependent on the COX2 pathway","volume":"310","author":"Otis","year":"2005","journal-title":"Exp. Cell Res."},{"issue":"3","key":"10.1016\/j.biopha.2018.12.034_bib0150","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2174\/1872208311206030223","article-title":"Prostaglandin E2: from clinical applications to its potential role in bone-muscle crosstalk and myogenic differentiation","volume":"6","author":"Mo","year":"2012","journal-title":"Recent Pat. Biotechnol."},{"issue":"4","key":"10.1016\/j.biopha.2018.12.034_bib0155","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1016\/S0021-9258(19)68084-1","article-title":"Arachidonic acid, prostaglandin E2 and F2 alpha influence rates of protein turnover in skeletal and cardiac muscle","volume":"257","author":"Rodemann","year":"1982","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.biopha.2018.12.034_bib0160","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1042\/bj2700045","article-title":"Prostaglandin E2 does not regulate total or myofibrillar protein breakdown in incubated skeletal muscle from normal or septic rats","volume":"270","author":"Hasselgren","year":"1990","journal-title":"Biochem. J."},{"key":"10.1016\/j.biopha.2018.12.034_bib0165","doi-asserted-by":"crossref","first-page":"177S","DOI":"10.1042\/bst019177s","article-title":"Prostaglandin metabolism in dystrophin-deficient MDX mouse muscle","volume":"19","author":"McArdle","year":"1991","journal-title":"Biochem. Soc. Trans."},{"issue":"1","key":"10.1016\/j.biopha.2018.12.034_bib0170","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.41.1.101","article-title":"Creatine kinase and prostaglandin E, release from isolated Duchenne muscle","volume":"41","author":"Jackson","year":"1991","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.biopha.2018.12.034_bib0175","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1093\/hmg\/ddm312","article-title":"Increased Gs signalling in platelets and impaired collagen activation, due to a defect in the dystrophin gene, result in increased blood loss during spinal surgery","volume":"17","author":"Labarque","year":"2008","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.biopha.2018.12.034_bib0180","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1172\/JCI113223","article-title":"Role of proaggregatory and antiaggregatory prostaglandins in hemostasis. Studies with combined thromboxane synthase inhibition and thromboxane receptor antagonism","volume":"80","author":"Gresele","year":"1987","journal-title":"J. Clin. Invest."},{"issue":"10","key":"10.1016\/j.biopha.2018.12.034_bib0185","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1038\/cdd.2008.90","article-title":"Prostaglandin F2\u03b1 promotes muscle cell survival and growth through upregulation of the inhibitor of apoptosis protein BRUCE","volume":"15","author":"Jansen","year":"2008","journal-title":"Cell Death Differ."},{"issue":"1-2","key":"10.1016\/j.biopha.2018.12.034_bib0190","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.mce.2010.01.023","article-title":"Prostaglandin D2 inhibits C2C12 myogenesis","volume":"319","author":"Veli\u00e7a","year":"2010","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.biopha.2018.12.034_bib0195","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.cca.2013.03.031","article-title":"A prostaglandin D 2 metabolite is elevated in the urine of Duchenne muscular dystrophy patients and increases further from 8years old","volume":"423","author":"Nakagawa","year":"2013","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.biopha.2018.12.034_bib0200","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1097\/01.ju.0000076390.30043.ff","article-title":"The cysteinyl-leukotriene D4 induces cytosolic Ca2+ elevation and contraction of the human detrusor muscle","volume":"170","author":"Bouchelouche","year":"2003","journal-title":"J. Urol."},{"key":"10.1016\/j.biopha.2018.12.034_bib0205","article-title":"Activated LTB4 pathway in muscle tissue of patients with polymyositis or dermatomyositis","author":"Loell","year":"2012","journal-title":"Ann. Rheum. Dis."},{"issue":"2","key":"10.1016\/j.biopha.2018.12.034_bib0210","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1182\/blood-2005-06-2362","article-title":"The leukotriene B 4 lipid chemoattractant receptor BLT1 defines antigen-primed T cells in humans","volume":"107","author":"Islam","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2018.12.034_bib0215","first-page":"395","article-title":"The expression of cyclooxygenase-1, cyclooxygenase-2 and 5-lipoxygenase in inflammatory muscle tissue of patients with polymyositis and dermatomyositis","volume":"22","author":"Studynkova","year":"2004","journal-title":"Clin. Exp. Rheumatol."},{"issue":"6","key":"10.1016\/j.biopha.2018.12.034_bib0220","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.braindev.2007.11.005","article-title":"Isoprostanes in dystrophinopathy: evidence of increased oxidative stress","volume":"30","author":"Grosso","year":"2008","journal-title":"Brain Dev."},{"issue":"21","key":"10.1016\/j.biopha.2018.12.034_bib0225","doi-asserted-by":"crossref","first-page":"9475","DOI":"10.1073\/pnas.92.21.9475","article-title":"Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions","volume":"92","author":"Claria","year":"1995","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.biopha.2018.12.034_bib0230","series-title":"Advances in Eicosanoid Research","first-page":"143","article-title":"Lipoxins, aspirin-triggered 15-epi-lipoxin stable analogs and their receptors in anti-inflammation: a window for therapeutic opportunity","author":"Serhan","year":"2000"},{"issue":"1","key":"10.1016\/j.biopha.2018.12.034_bib0235","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1177\/039463200401700103","article-title":"Lipoxin A4 counteracts synergistic activation of human fibroblast-like synoviocytes","volume":"17","author":"Sodin-Semrl","year":"2004","journal-title":"Int. J. Immunopathol. Pharmacol."},{"issue":"3","key":"10.1016\/j.biopha.2018.12.034_bib0240","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1177\/088307380201700306","article-title":"Corticosteroids in Duchenne muscular dystrophy: a reappraisal","volume":"17","author":"Wong","year":"2002","journal-title":"J. Child Neurol."},{"issue":"9","key":"10.1016\/j.biopha.2018.12.034_bib0245","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1002\/1097-4598(200009)23:9<1344::AID-MUS4>3.0.CO;2-F","article-title":"A multicenter, double\u2010blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy","volume":"23","author":"Bonifati","year":"2000","journal-title":"Muscle Nerve"},{"issue":"5","key":"10.1016\/j.biopha.2018.12.034_bib0250","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1212\/WNL.0b013e318227b164","article-title":"Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophy","volume":"77","author":"Escolar","year":"2011","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.biopha.2018.12.034_bib0255","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S0304-3940(99)00418-8","article-title":"The effect of methylprednisolone on intracellular calcium of normal and dystrophic human skeletal muscle cells","volume":"269","author":"Vandebrouck","year":"1999","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.biopha.2018.12.034_bib0260","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/0960-8966(94)00042-8","article-title":"The effect of glucocorticoids on the accumulation of utrophin by cultured normal and dystrophic human skeletal muscle satellite cells","volume":"5","author":"Pasquini","year":"1995","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.biopha.2018.12.034_bib0265","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.nmd.2007.02.005","article-title":"Strength and corticosteroid responsiveness of mdx mice is unchanged by RAG2 gene knockout","volume":"17","author":"Golumbek","year":"2007","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.biopha.2018.12.034_bib0270","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003725.pub3","article-title":"Glucocorticoid corticosteroids for Duchenne muscular dystrophy","volume":"1","author":"Manzur","year":"2008","journal-title":"Cochrane Database Syst. Rev."},{"issue":"5","key":"10.1016\/j.biopha.2018.12.034_bib0275","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1007\/BF00869001","article-title":"Prednisone can protect against exercise-induced muscle damage","volume":"243","author":"Jacobs","year":"1996","journal-title":"J. Neurol."},{"issue":"2","key":"10.1016\/j.biopha.2018.12.034_bib0280","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/mus.880060204","article-title":"Clinical investigation in Duchenne dystrophy: 2. Determination of the \u201cpower\u201d of therapeutic trials based on the natural history","volume":"6","author":"Brooke","year":"1983","journal-title":"Muscle Nerve"},{"issue":"5","key":"10.1016\/j.biopha.2018.12.034_bib0285","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1002\/mus.23432","article-title":"Inflammation in muscular dystrophy and the beneficial effects of non\u2010steroidal anti\u2010inflammatory drugs","volume":"46","author":"Serra","year":"2012","journal-title":"Muscle Nerve"},{"issue":"1","key":"10.1016\/j.biopha.2018.12.034_bib0290","first-page":"11","article-title":"Pharmacological studies on the novel antiallergic drug HQL-79: II. Elucidation of mechanisms for antiallergic and antiasthmatic effects","volume":"78","author":"Matsushita","year":"2001","journal-title":"Jpn. J. Pharmacol."},{"key":"10.1016\/j.biopha.2018.12.034_bib0295","series-title":"Functional and Structural Biology on the Lipo-network","first-page":"135","article-title":"Biochemical and structural characteristics of hematopoietic prostaglandin D synthase: from evolutionary analysis to drug designing","author":"Urade","year":"2006"},{"issue":"5","key":"10.1016\/j.biopha.2018.12.034_bib0300","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.2353\/ajpath.2009.080709","article-title":"Inhibition of prostaglandin D synthase suppresses muscular necrosis","volume":"174","author":"Mohri","year":"2009","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.biopha.2018.12.034_bib0305","first-page":"1261","article-title":"Hematopoietic prostaglandin d synthase inhibitors for the treatment of duchenne muscular dystrophy","author":"Kamauchi","year":"2011","journal-title":"Brain Nerve"},{"issue":"1","key":"10.1016\/j.biopha.2018.12.034_bib0310","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13023-015-0311-0","article-title":"Naproxcinod shows significant advantages over naproxen in the mdx model of Duchenne Muscular Dystrophy","volume":"10","author":"Miglietta","year":"2015","journal-title":"Orphanet J. Rare Dis."},{"issue":"3","key":"10.1016\/j.biopha.2018.12.034_bib0315","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.phrs.2011.05.003","article-title":"A dual acting compound releasing nitric oxide (NO) and ibuprofen, NCX 320, shows significant therapeutic effects in a mouse model of muscular dystrophy","volume":"64","author":"Sciorati","year":"2011","journal-title":"Pharmacol. Res."},{"issue":"1","key":"10.1016\/j.biopha.2018.12.034_bib0320","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1073\/pnas.0608277104","article-title":"Nitric oxide release combined with nonsteroidal antiinflammatory activity prevents muscular dystrophy pathology and enhances stem cell therapy","volume":"104","author":"Brunelli","year":"2007","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"12","key":"10.1016\/j.biopha.2018.12.034_bib0325","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1002\/art.27694","article-title":"Efficacy, safety, and effects on blood pressure of naproxcinod 750 mg twice daily compared with placebo and naproxen 500 mg twice daily in patients with osteoarthritis of the hip: a randomized, double\u2010blind, parallel\u2010group, multicenter study","volume":"62","author":"Baerwald","year":"2010","journal-title":"Arthritis Rheumatol."},{"issue":"2","key":"10.1016\/j.biopha.2018.12.034_bib0330","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1053\/gast.2000.9304","article-title":"Nitric oxide in mucosal defense: a little goes a long way","volume":"119","author":"Wallace","year":"2000","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.biopha.2018.12.034_bib0335","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.phrs.2012.01.006","article-title":"Nitric oxide donor and non steroidal anti inflammatory drugs as a therapy for muscular dystrophies: evidence from a safety study with pilot efficacy measures in adult dystrophic patients","volume":"65","author":"D\u2019Angelo","year":"2012","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.biopha.2018.12.034_bib0340","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.phrs.2013.04.009","article-title":"Ibuprofen plus isosorbide dinitrate treatment in the mdx mice ameliorates dystrophic heart structure","volume":"73","author":"Sciorati","year":"2013","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.biopha.2018.12.034_bib0345","first-page":"411","article-title":"Combined isosorbide dinitrate and ibuprofen as a novel therapy for muscular dystrophies: evidence from Phase I studies in healthy volunteers","volume":"8","author":"Cossu","year":"2014","journal-title":"Drug Des. Devel. Ther."},{"issue":"5","key":"10.1016\/j.biopha.2018.12.034_bib0350","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/0092-8674(95)90471-9","article-title":"Nitric oxide synthase complexed with dystrophin and absent from skeletal muscle sarcolemma in Duchenne muscular dystrophy","volume":"82","author":"Brenman","year":"1995","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.biopha.2018.12.034_bib0355","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1152\/physrev.2001.81.1.209","article-title":"Physiology of nitric oxide in skeletal muscle","volume":"81","author":"Stamler","year":"2001","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.biopha.2018.12.034_bib0360","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1161\/01.HYP.31.1.218","article-title":"Phospholipase A2-metabolites regulate inducible nitric oxide synthase in myocytes","volume":"31","author":"LaPointe","year":"1998","journal-title":"Hypertension"},{"key":"10.1016\/j.biopha.2018.12.034_bib0365","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1016\/j.lfs.2005.03.023","article-title":"The anti-apoptotic effects of nordihydroguaiaretic acid: inhibition of cPLA(2) activation during TNF-induced apoptosis arises from inhibition of calcium signaling","volume":"77","author":"Culver","year":"2005","journal-title":"Life Sci."},{"key":"10.1016\/j.biopha.2018.12.034_bib0370","first-page":"252","article-title":"Role of arachidonic acid metabolites in transcriptional induction of tumor necrosis factor gene expression by phorbol ester","volume":"9","author":"Horiguchi","year":"1989","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.biopha.2018.12.034_bib0375","first-page":"181","article-title":"Lipoxins: nature\u2019s way to resolve inflammation","volume":"8","author":"Chandrasekharan","year":"2015","journal-title":"J. Inflamm. Res."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332218367660?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332218367660?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T21:16:20Z","timestamp":1764105380000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332218367660"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":75,"alternative-id":["S0753332218367660"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2018.12.034","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Duchenne muscular dystrophy: Focus on arachidonic acid metabolites","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2018.12.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Author. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}